About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -10.56$ per share.

The book value per share is 0.70$

Edesa Biotech, Inc. website

Create a solid portfolio with EDSA

Add EDSA to your portfolio and optimize it!


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- -37.70% -5M -386.00% -5M -10.56 - - 9M 0.70 -5M - -5M